Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash from Investing Activities: 2018-2024

Historic Cash from Investing Activities for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to -$554.4 million.

  • Revolution Medicines' Cash from Investing Activities rose 215.74% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$349.7 million, marking a year-over-year increase of 35.46%. This contributed to the annual value of -$554.4 million for FY2024, which is 61.82% down from last year.
  • According to the latest figures from FY2024, Revolution Medicines' Cash from Investing Activities is -$554.4 million, which was down 61.82% from -$342.6 million recorded in FY2023.
  • In the past 5 years, Revolution Medicines' Cash from Investing Activities registered a high of -$24.1 million during FY2022, and its lowest value of -$554.4 million during FY2024.
  • For the 3-year period, Revolution Medicines' Cash from Investing Activities averaged around -$307.0 million, with its median value being -$342.6 million (2023).
  • As far as peak fluctuations go, Revolution Medicines' Cash from Investing Activities skyrocketed by 83.03% in 2022, and later plummeted by 1,320.63% in 2023.
  • Revolution Medicines' Cash from Investing Activities (Yearly) stood at -$234.2 million in 2020, then spiked by 39.33% to -$142.1 million in 2021, then soared by 83.03% to -$24.1 million in 2022, then tumbled by 1,320.63% to -$342.6 million in 2023, then crashed by 61.82% to -$554.4 million in 2024.